Sales

Novartis has asked the FDA to extend the review period for its highly anticipated developmental diabetes drug Galvus by three months to allow the agency to examine new clinical trials data.

Genentech has agreed to acquire its Xolair co-marketer, the Houston-based biotech firm Tanox, in a deal worth $919 million.

3M has agreed to sell-off its global pharmaceuticals business, which makes dermatology, women’s health, cardiology and respiratory treatments, for $2.1 billion.

Abbott has agreed to buy specialty firm Kos for $3.7 billion, a move that complements its cardiovascular franchise and boosts its pipeline.

The prices being paid in the recent rash of pharmaceutical acquisition deals are “breath-taking,” Schering-Plough CEO Fred Hassan said in an interview with Marketwatch.com.

The California attorney general’s office expanded its probe into the marketing of anti-psychotic drugs, serving subpoenas to Eli Lilly and Bristol-Myers Squibb, the companies have said.

Pfizer confirmed that its leading pipeline candidate torcetrapib raised blood pressure in clinical trial patients more than previously reported.

The California attorney general’s office expanded its probe into the marketing of anti-psychotic drugs, serving subpoenas to Eli Lilly and Bristol-Myers Squibb, the companies have said.

Behavioral change-focused relationship marketing firm HealthMedia announced today that it has acquired the consumer Web site MySelfHelp.com.

Nearly 40% of scientists researching diseases and cures at the National Institutes of Health (NIH) are considering new jobs to escape strict ethics rules, a recent survey said.